New haemophilia drug Inno8 tested in healthy volunteers
NCT ID NCT06649630
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 37 times
Summary
This completed Phase 1 trial tested the safety of a new drug called Inno8 in 95 healthy men. Participants received either Inno8 or a placebo by injection or as tablets. The study measured side effects and how the drug moves through the body. Results will help decide if Inno8 should be tested further in people with haemophilia A.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMOPHILIA A are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inno8 (NNC0442-0344 A)
What this could lead to
If this early safety trial succeeds, it could support further development of Inno8 as a potential treatment for haemophilia A.
What could go wrong
This is a very early Phase 1 trial in only 95 healthy men, not people with haemophilia. It is designed only to check safety and dosing, not to prove the drug works. Many drugs fail in later stages.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.